DRMA

Dermata Therapeutics, Inc. (DRMA) | Rumor.io

Dermata Therapeutics

DRMA

Attention (50-day avg)0%

Attention rank (50-day avg)#1,699

Bullish sentiment (50-day avg)62%

Price to earnings ratio0.1

Market capitalization5.5M

Earnings per share-4.13

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-7.6M

Social

What share of all stock conversation is about DRMA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Aug 13

Dermata Therapeutics, Inc. (DRMA) is an American biotechnology and skincare brand, not a Chinese brand as previously stated.
The company's product launch on August 25, 2026, is expected to create a fundamental shift by adding a new revenue stream to the balance sheet.
DRMA's stock is predicted to run up, with some analysts expecting it to reach a 52-week high before the product launch, and others anticipating a slow grind up on a better future outlook.

Generated by AI

Sentiment

Of the messages about DRMA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +20	85.21% -0.7
Bearish	—	0%	0% -20	14.79% +0.7

Bullish· Aug 12

The upcoming launch of Dermata Therapeutics' product on August 25 is expected to be a major catalyst for the company, potentially creating a new revenue-generating platform and supporting future skincare products.
The launch of the product on August 25 is also expected to attract increased investor attention, as it marks a significant step toward a consumer-focused skincare business and could lead to further momentum in the stock price.
Dermata Therapeutics' Bioneedle technology has the potential to support future skincare products, and the company's strong price movement and growing investor interest suggest a clear bullish trend ahead of the August 25 launch.

Bearish· Aug 11

The stock has performed terribly over the past 1-year and 5-years, with a -82% and -99.99% decline respectively.
The company has a history of struggling with news and announcements, despite being able to run hundreds of percent per day with fake scandals.
The stock is expected to continue its downward trend, with one user stating that if you can't hold the price here, you don't deserve to trade.

Generated by AI

Topics

Of the messages about DRMA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	21.14%
Technical Analysis	—	—	0%	22.45%
Earnings	—	—	0%	0.13%
Analysts	—	—	0%	28.27%
Controversies	—	—	0%	0.2%
Macro	—	—	0%	27.81%

Announcements· Jan 27

Dermata Therapeutics, Inc. (DRMA) surges to $3.08 +41.94% on a key patent grant in Australia for its next-gen acne treatment, solidifying its IP moat and commercial potential.
The Australian patent grant reinforces DRMA's IP portfolio and commercial pathway, following the recent U.S. issuance, and supports the upcoming launch of its once-weekly product.
The patent grant is a significant regulatory milestone, expanding DRMA's commercial pathway for its Spongilla technology and validating the innovation pipeline, with bullish prospects for the clinical pathway.

Technical Analysis· Feb 19

$DRMA is breaking out on volume, with a momentum-driven move expected if it can hold above $2.
The stock has a low float of 2.5M and has shown significant price movement, with a potential target of $3.27 if it can break through the $2 level.
The stock's technical analysis suggests a strong trend reversal, with multiple indicators showing positive divergences and a potential long-term trend reversal.

Generated by AI

Community

Of the messages about DRMA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	85.71%	31.93%
Newcomers	0%	0%	14.29%	68.07%

Regulars· Aug 12

The regulars believe that Dermata Therapeutics, Inc. ($DRMA) will experience a significant price increase after its product launch, with some predicting a run to $1.5 or even $2.
There is concern about the lack of trading volume, with one participant noting that it's "crazy" and that there isn't enough volume for anyone to have bought lower to sell at these prices for profit.
The company's earnings in loss and the fact that it's too far away from the next earnings release on August 25 are seen as potential drawbacks, but the regulars remain optimistic about the company's future prospects.

Newcomers· Aug 13

Many newcomers are discussing DRMA's upcoming direct-to-consumer skincare product, the Tome Foundational Treatment, and its potential impact on the stock price.
Some users are looking for a good entry point to buy DRMA, considering it a good value at prices below $1.40, with the product launch on August 25 being a key catalyst.
Others are speculating about a potential reverse split, citing the stock's recent price movements and the importance of being cautious at these levels.

Generated by AI

SAN DIEGO, CA / ACCESS Newswire / August 25, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced the official commercial launch of the Tome Foundational Treatment, the first product available for purchase under the Company's Tome skincare brand. The Foundational Treatment is now available for immediate purchase at www.tomeskincare.com, either as a one-time purchase or through a monthly subscription at a discounted price. The commercial launch marks a significant landmark in Dermata's evolution into a direct-to-consumer skincare company and represents the Company's first commercial product under the Tome brand.

1mo agoYahoo Finance

Dermata opens preorders for Tome skincare product

1mo agoInvesting.com

Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch

- Preorders can be made by visiting www.tomeskincare.com - - Dermata is ready to begin shipping orders on the expected launch date of August 25, 2026 - - Tome Foundational Treatment is a once-weekly topical mask for skin renewal - SAN DIEGO, CA / ...

1mo agoYahoo Finance

Dermata Therapeutics raises $3.4 million in private placement

1mo agoInvesting.com

Also Discussed

Investors talking about DRMA also mention

#	Name	Attention
1	Silo Pharma Inc.SILO	0%new
2	Cardio Diagnostics Holdings, Inc.CDIO	0%0
3	LIPO - Lipella Pharmaceuticals Inc.	——
4	ASNS - Actelis Networks, Inc.	——
5	ACHL - Achilles Therapeutics plc	——
6	MKDWELL Tech Inc.MKDW	0%+0
7	PBLA - Panbela Therapeutics, Inc.	——
8	Revelation Biosciences Inc.REVB	0%0
9	SMFL - Smart for Life, Inc.	——
10	PaxMedica Inc.PXMD	0%0

Dermata Therapeutics, Inc.

Healthcare
Biotechnology

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company focused on developing and commercializing products for medical and aesthetic skin conditions. The company currently works on topical dermatologic solutions that leverage its proprietary technology platform to target a range of skin disorders and cosmetic applications. Its product pipeline includes treatments designed for conditions such as acne, psoriasis, rosacea, and hyperhidrosis, as well as needle-free intradermal delivery approaches for aesthetic uses. Dermata Therapeutics also operates in the direct-to-consumer skincare market through the Tome brand, reflecting its broader emphasis on skin renewal and everyday dermatologic care. Headquartered in San Diego, California, Dermata Therapeutics serves as a specialized participant in the dermatology market, combining pharmaceutical development with consumer skincare products aimed at skin health and appearance.

Website

Location

3525 Del Mar Heights Rd.

San Diego, CA, 92130

United States

Social

What share of all stock conversation is about DRMA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Aug 13

Dermata Therapeutics, Inc. (DRMA) is an American biotechnology and skincare brand, not a Chinese brand as previously stated.
The company's product launch on August 25, 2026, is expected to create a fundamental shift by adding a new revenue stream to the balance sheet.
DRMA's stock is predicted to run up, with some analysts expecting it to reach a 52-week high before the product launch, and others anticipating a slow grind up on a better future outlook.

Generated by AI

Sentiment

Of the messages about DRMA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +20	85.21% -0.7
Bearish	—	0%	0% -20	14.79% +0.7

Bullish· Aug 12

The upcoming launch of Dermata Therapeutics' product on August 25 is expected to be a major catalyst for the company, potentially creating a new revenue-generating platform and supporting future skincare products.
The launch of the product on August 25 is also expected to attract increased investor attention, as it marks a significant step toward a consumer-focused skincare business and could lead to further momentum in the stock price.
Dermata Therapeutics' Bioneedle technology has the potential to support future skincare products, and the company's strong price movement and growing investor interest suggest a clear bullish trend ahead of the August 25 launch.

Bearish· Aug 11

The stock has performed terribly over the past 1-year and 5-years, with a -82% and -99.99% decline respectively.
The company has a history of struggling with news and announcements, despite being able to run hundreds of percent per day with fake scandals.
The stock is expected to continue its downward trend, with one user stating that if you can't hold the price here, you don't deserve to trade.

Generated by AI

Topics

Of the messages about DRMA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	21.14%
Technical Analysis	—	—	0%	22.45%
Earnings	—	—	0%	0.13%
Analysts	—	—	0%	28.27%
Controversies	—	—	0%	0.2%
Macro	—	—	0%	27.81%

Announcements· Jan 27

Dermata Therapeutics, Inc. (DRMA) surges to $3.08 +41.94% on a key patent grant in Australia for its next-gen acne treatment, solidifying its IP moat and commercial potential.
The Australian patent grant reinforces DRMA's IP portfolio and commercial pathway, following the recent U.S. issuance, and supports the upcoming launch of its once-weekly product.
The patent grant is a significant regulatory milestone, expanding DRMA's commercial pathway for its Spongilla technology and validating the innovation pipeline, with bullish prospects for the clinical pathway.

Technical Analysis· Feb 19

$DRMA is breaking out on volume, with a momentum-driven move expected if it can hold above $2.
The stock has a low float of 2.5M and has shown significant price movement, with a potential target of $3.27 if it can break through the $2 level.
The stock's technical analysis suggests a strong trend reversal, with multiple indicators showing positive divergences and a potential long-term trend reversal.

Generated by AI

Community

Of the messages about DRMA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	85.71%	31.93%
Newcomers	0%	0%	14.29%	68.07%

Regulars· Aug 12

The regulars believe that Dermata Therapeutics, Inc. ($DRMA) will experience a significant price increase after its product launch, with some predicting a run to $1.5 or even $2.
There is concern about the lack of trading volume, with one participant noting that it's "crazy" and that there isn't enough volume for anyone to have bought lower to sell at these prices for profit.
The company's earnings in loss and the fact that it's too far away from the next earnings release on August 25 are seen as potential drawbacks, but the regulars remain optimistic about the company's future prospects.

Newcomers· Aug 13

Many newcomers are discussing DRMA's upcoming direct-to-consumer skincare product, the Tome Foundational Treatment, and its potential impact on the stock price.
Some users are looking for a good entry point to buy DRMA, considering it a good value at prices below $1.40, with the product launch on August 25 being a key catalyst.
Others are speculating about a potential reverse split, citing the stock's recent price movements and the importance of being cautious at these levels.

Generated by AI

Dermata Therapeutics

Social

Aug 13

Bullish· Aug 12

Bearish· Aug 11

Announcements· Jan 27

Technical Analysis· Feb 19

Regulars· Aug 12

Newcomers· Aug 13

12 Health Care Stocks Moving In Tuesday's After-Market Session

Dermata launches first direct-to-consumer skincare product

Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment

Dermata opens preorders for Tome skincare product

Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch

Dermata Therapeutics raises $3.4 million in private placement

Also Discussed

Dermata Therapeutics, Inc.

Company Information

Location

12 Health Care Stocks Moving In Tuesday's After-Market Session

Dermata launches first direct-to-consumer skincare product

Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment

Dermata opens preorders for Tome skincare product

Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch

Dermata Therapeutics raises $3.4 million in private placement

Also Discussed

Social

Aug 13

Bullish· Aug 12

Bearish· Aug 11

Announcements· Jan 27

Technical Analysis· Feb 19

Regulars· Aug 12

Newcomers· Aug 13